Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.95 USD | -0.07% |
|
-5.35% | +41.25% |
Jul. 01 | RxSight, Inc.(NasdaqGM:RXST) dropped from Russell Microcap Growth Index | CI |
Jul. 01 | RxSight, Inc.(NasdaqGM:RXST) dropped from Russell 3000E Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+41.25% | 2.22B | D | ||
-5.50% | 181B | C+ | ||
-5.79% | 99.52B | C | ||
-6.59% | 65.82B | A | ||
-8.38% | 45.21B | B- | ||
+8.42% | 43.85B | B- | ||
+10.10% | 42.17B | B+ | ||
+10.97% | 28.75B | B | ||
+18.89% | 25.39B | A- | ||
-8.39% | 23.5B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RXST Stock
- Ratings RxSight, Inc.